Johnson & Johnson Reports Promising TALVEY Blood Cancer Trial Results

Johnson & Johnson (JNJ) announced positive results from a late-stage clinical trial of its blood cancer drug TALVEY (for multiple myeloma) on June 13. The data comes as the company seeks to prove it can continue growing after losing patent protection for its blockbuster drug Stelara.

Trial Details

The Phase 3 trial showed that TALVEY achieved promising results in patients with relapsed or refractory multiple myeloma. The company did not disclose specific data but described the results as "encouraging" and "supporting a potential regulatory filing."

Pricing and Availability

JNJ has not yet announced pricing or availability for TALVEY. The company is expected to submit a Biologics License Application (BLA) to the FDA in the coming months.

Competition

TALVEY faces competition from other multiple myeloma treatments such as Darzalex (also from JNJ's Janssen unit) and Tecvayli (Janssen). However, TALVEY could offer a new option for patients who have failed prior therapies.

Potential Impact on the Company

These results are a key step in JNJ's strategy to diversify its drug portfolio and offset revenue losses from Stelara. Analysts estimate TALVEY could generate $1-2 billion in annual sales if approved.